History of STX-101
Phase 1 Studies Conducted
STX-101 Advances with Phase 1 Success, Titration Path Set
Clean safety profile, predictable pharmacokinetics, and early efficacy signals de-risk the programme and support rapid Phase 2 initiation
Unified Data Engine for Accelerated, Compliant Evidence
End-to-end digital capture unifies patient onboarding, monitoring, and analysis—delivering four-times-faster validation with documentation ready for regulators and payers
Future Milestones
